Identification

Name
Nalbuphine
Accession Number
DB00844  (APRD01132)
Type
Small Molecule
Groups
Approved
Description

A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.

Structure
Thumb
Synonyms
  • N-Cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriol
  • Nalbufina
  • Nalbuphin
  • Nalbuphine
  • Nalbuphinum
External IDs
EN-2234 A
Product Ingredients
IngredientUNIICASInChI Key
Nalbuphine hydrochlorideZU4275277R23277-43-2YZLZPSJXMWGIFH-BCXQGASESA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nubain Injection 10mg/mlSolution10 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1993-12-31Not applicableCanada
Nubain Injection 20mg/mlSolution20 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1993-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nalbuphine HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousCardinal Health1989-02-032017-11-07Us
Nalbuphine HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1989-02-03Not applicableUs
Nalbuphine HydrochlorideInjection, solution20 mg/mLIntramuscular; Intravenous; SubcutaneousMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2010-05-03Not applicableUs
Nalbuphine HydrochlorideInjection, solution20 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1989-02-03Not applicableUs
Nalbuphine HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1989-02-03Not applicableUs
Nalbuphine HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousCardinal Health1989-02-03Not applicableUs
Nalbuphine HydrochlorideInjection, solution20 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.1989-02-03Not applicableUs
Nalbuphine HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousGeneral Injectables & Vaccines2010-03-01Not applicableUs
International/Other Brands
Mexifen (Medicus) / Nalbuphine (Mylan) / Nalpain (Orpha-Devel) / Nubain (Sandoz)
Categories
UNII
L2T84IQI2K
CAS number
20594-83-6
Weight
Average: 357.4434
Monoisotopic: 357.194008357
Chemical Formula
C21H27NO4
InChI Key
NETZHAKZCGBWSS-CEDHKZHLSA-N
InChI
InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
IUPAC Name
(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene-10,14,17-triol
SMILES

Pharmacology

Indication

For the relief of moderate to severe pain.

Structured Indications
Pharmacodynamics

Nalbuphine is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. Nalbuphine's analgesic potency is essentially equivalent to that of morphine on a milligram basis. The opioid antagonist activity of nalbuphine is one-fourth as potent as nalorphine and 10 times that of pentazocine. Nalbuphine by itself has potent opioid antagonist activity at doses equal to or lower than its analgesic dose. When administered following or concurrent with mu agonist opioid analgesics (e.g., morphine, oxymorphone, fentanyl), nalbuphine may partially reverse or block opioid-induced respiratory depression from the mu agonist analgesic. Nalbuphine may precipitate withdrawal in patients dependent on opioid drugs. Nalbuphine should be used with caution in patients who have been receiving mu opioid analgesics on a regular basis.

Mechanism of action

The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.

TargetActionsOrganism
AKappa-type opioid receptor
agonist
Human
AMu-type opioid receptor
antagonist
Human
ADelta-type opioid receptor
antagonist
Human
Absorption

The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.

Volume of distribution
Not Available
Protein binding

Not appreciably bound.

Metabolism
Not Available
Route of elimination
Not Available
Half life

The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.

Clearance
Not Available
Toxicity

Oral, acute LD50 is 1100 mg/kg in dog. Symptoms of overdose include primarily sleepiness and mild dysphoria.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nalbuphine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Nalbuphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Nalbuphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Nalbuphine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Nalbuphine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Agomelatine.Approved, Investigational
AlaproclateNalbuphine may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Nalbuphine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nalbuphine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Nalbuphine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nalbuphine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Nalbuphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Nalbuphine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Nalbuphine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Asenapine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Nalbuphine.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nalbuphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Nalbuphine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Azaperone.Investigational, Vet Approved
AzelastineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Nalbuphine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Nalbuphine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Nalbuphine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benzyl alcohol.Approved
BezitramideNalbuphine may decrease the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Nalbuphine.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Nalbuphine.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Nalbuphine.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bupivacaine.Approved, Investigational
BuprenorphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nalbuphine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nalbuphine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nalbuphine.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Nalbuphine.Approved, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nalbuphine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nalbuphine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Nalbuphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Nalbuphine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Nalbuphine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nalbuphine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cinchocaine.Approved, Vet Approved
CitalopramNalbuphine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nalbuphine.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nalbuphine.Approved
CocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Nalbuphine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Nalbuphine.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dapiprazole.Approved
DapoxetineNalbuphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Nalbuphine.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.Approved
DesvenlafaxineNalbuphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Nalbuphine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Nalbuphine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nalbuphine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Nalbuphine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Nalbuphine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Drotebanol.Experimental, Illicit
DuloxetineNalbuphine may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Eltanolone.Investigational
EluxadolineNalbuphine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Nalbuphine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Eplerenone.Approved
EscitalopramNalbuphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nalbuphine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Nalbuphine.Experimental
EthanolNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Nalbuphine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etomidate.Approved
EtoperidoneNalbuphine may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Nalbuphine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nalbuphine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Nalbuphine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flunitrazepam.Approved, Illicit
FluoxetineNalbuphine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nalbuphine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nalbuphine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Nalbuphine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Nalbuphine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Nalbuphine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Nalbuphine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nalbuphine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Nalbuphine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Nalbuphine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nalbuphine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Nalbuphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Nalbuphine.Approved
IbopamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Imipramine.Approved
IndalpineNalbuphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Nalbuphine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Nalbuphine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nalbuphine.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Isosorbide.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranNalbuphine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Nalbuphine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nalbuphine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nalbuphine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Nalbuphine.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nalbuphine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Nalbuphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Nalbuphine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nalbuphine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Nalbuphine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Nalbuphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Nalbuphine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Nalbuphine.Approved
MethotrimeprazineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Nalbuphine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Nalbuphine.Approved, Investigational
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Nalbuphine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Nalbuphine.Approved
MeticraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Nalbuphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone.Approved
MetyrosineNalbuphine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nalbuphine.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of Nalbuphine.Experimental, Illicit, Investigational
MilnacipranNalbuphine may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved, Investigational
MirtazapineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Nalbuphine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Nalbuphine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nalbuphine.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved, Investigational
NaloxegolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Naloxegol.Approved
NaltrexoneThe therapeutic efficacy of Nalbuphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneNalbuphine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nialamide.Withdrawn
NicomorphineNalbuphine may decrease the analgesic activities of Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nalbuphine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Opium.Approved, Illicit
OrphenadrineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Nalbuphine.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nalbuphine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Nalbuphine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Nalbuphine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nalbuphine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Nalbuphine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone.Approved
PamabromThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pamabrom.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Nalbuphine.Approved
ParaldehydeNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pargyline.Approved
ParoxetineNalbuphine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nalbuphine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nalbuphine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Nalbuphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
PerazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nalbuphine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Nalbuphine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Nalbuphine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nalbuphine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Nalbuphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleNalbuphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nalbuphine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nalbuphine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Nalbuphine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Nalbuphine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Nalbuphine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Proparacaine.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Nalbuphine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Nalbuphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Nalbuphine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nalbuphine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Nalbuphine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Nalbuphine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Nalbuphine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ramelteon.Approved, Investigational
RamosetronNalbuphine may increase the constipating activities of Ramosetron.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nalbuphine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Nalbuphine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Nalbuphine.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Romifidine.Vet Approved
RopiniroleNalbuphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ropivacaine.Approved
RotigotineNalbuphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nalbuphine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nalbuphine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineNalbuphine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Nalbuphine.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Nalbuphine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nalbuphine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sultopride.Experimental
SuvorexantNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nalbuphine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrodotoxin.Investigational
ThalidomideNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Nalbuphine.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Nalbuphine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Nalbuphine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nalbuphine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Nalbuphine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Nalbuphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nalbuphine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nalbuphine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Nalbuphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Nalbuphine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Nalbuphine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Nalbuphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Nalbuphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nalbuphine.Approved
UlaritideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Nalbuphine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Nalbuphine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nalbuphine.Approved
VenlafaxineNalbuphine may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ziconotide.Approved
ZimelidineNalbuphine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Nalbuphine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zolazepam.Vet Approved
ZolpidemNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Michael R. Magruder, "Nalbuphine-narcotic analgesic composition and method of producing analgesia." U.S. Patent US4366159, issued August, 1981.

US4366159
General References
  1. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 Nov;83(2):339-45. [PubMed:10534607]
External Links
Human Metabolome Database
HMDB14982
KEGG Drug
D08246
KEGG Compound
C07251
PubChem Compound
5311304
PubChem Substance
46507383
ChemSpider
4470813
BindingDB
50105085
ChEBI
7454
ChEMBL
CHEMBL895
Therapeutic Targets Database
DAP000380
PharmGKB
PA164745372
IUPHAR
1663
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nalbuphine
ATC Codes
N02AF02 — Nalbuphine
AHFS Codes
  • 28:08.12 — Opiate Partial Agonists
FDA label
Download (51.4 KB)
MSDS
Download (74.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAnalgesia Disorder / Pain1
1CompletedTreatmentUremic Pruritus1
1RecruitingTreatmentPharmacokinetics1
1Unknown StatusNot AvailableHealthy Volunteers1
2CompletedPreventionRotator Cuff Syndrome1
2, 3Active Not RecruitingTreatmentNodularis Prurigo / Prurigo Nodularis / Rash pruritic1
2, 3CompletedTreatmentNodularis Prurigo / Prurigo Nodularis / Pruritus / Rash pruritic1
2, 3CompletedTreatmentPruritus / Uremic Pruritus2
3Active Not RecruitingTreatmentPain / Sickle Cell Disorders1
3CompletedTreatmentPruritis1
4CompletedPreventionCesarean Section1
4CompletedTreatmentInadequate or Impaired Respiratory Function / Pain1
4RecruitingTreatmentNalbuphine , Morphine / Postoperative pain1
4Unknown StatusTreatmentPostoperative pain1
Not AvailableCompletedDiagnosticConscious Sedation Failure During Procedure1
Not AvailableCompletedPreventionPostoperative pain1
Not AvailableNot Yet RecruitingTreatmentC.Delivery; Surgery (Previous), Gynecological1
Not AvailableRecruitingTreatmentAnaesthesia therapy / General Surgery / Prophylaxis against postoperative nausea and vomiting1
Not AvailableTerminatedBasic ScienceHealthy Volunteers1
Not AvailableTerminatedTreatmentPain1
Not AvailableUnknown StatusNot AvailableHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous; Subcutaneous10 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous20 mg/mL
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
SolutionIntramuscular; Intravenous; Subcutaneous20 mg
Prices
Unit descriptionCostUnit
Nubain 20 mg/ml ampule4.9USD ml
Nubain 10 mg/ml vial3.53USD ml
Nalbuphine 20 mg/ml ampul3.2USD ml
Nalbuphine 200 mg/10 ml vial2.66USD ml
Nalbuphine 10 mg/ml ampul1.46USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)230 °C as HCl saltNot Available
water solubility35.5 mg/mL at 25 °C as HCl saltNot Available
logP1.4Not Available
pKa8.71 and 9.96 (hcl form)FDA Label
Predicted Properties
PropertyValueSource
Water Solubility2.09 mg/mLALOGPS
logP2ALOGPS
logP1.19ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)7.45ChemAxon
pKa (Strongest Basic)13.75ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area73.16 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97 m3·mol-1ChemAxon
Polarizability38.59 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.968
Blood Brain Barrier+0.9642
Caco-2 permeable+0.7337
P-glycoprotein substrateSubstrate0.8532
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8923
Renal organic cation transporterInhibitor0.5431
CYP450 2C9 substrateNon-substrate0.8645
CYP450 2D6 substrateSubstrate0.5896
CYP450 3A4 substrateSubstrate0.5919
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9421
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9029
CYP450 3A4 inhibitorNon-inhibitor0.93
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9562
Ames testNon AMES toxic0.6897
CarcinogenicityNon-carcinogens0.9598
BiodegradationNot ready biodegradable0.9796
Rat acute toxicity2.6502 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.747
hERG inhibition (predictor II)Non-inhibitor0.8054
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Tetralins / Coumarans / 1-hydroxy-2-unsubstituted benzenoids / Alkyl aryl ethers / Aralkylamines / Piperidines / Tertiary alcohols / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols
show 6 more
Substituents
Phenanthrene / Tetralin / Coumaran / 1-hydroxy-2-unsubstituted benzenoid / Alkyl aryl ether / Aralkylamine / Piperidine / Cyclic alcohol / Tertiary alcohol / 1,2-aminoalcohol
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound (CHEBI:7454)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hoehe M, Duka T: Opiates increase plasma catecholamines in humans. Psychoneuroendocrinology. 1993;18(2):141-8. [PubMed:8388112]
  4. Chen SL, Huang EY, Chow LH, Tao PL: Dextromethorphan differentially affects opioid antinociception in rats. Br J Pharmacol. 2005 Feb;144(3):400-4. [PubMed:15655510]
  5. Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend. 2006 Sep 15;84(2):175-81. Epub 2006 Mar 6. [PubMed:16517095]
  6. Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN: The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther. 2009 Aug;330(2):468-75. doi: 10.1124/jpet.108.150011. Epub 2009 Apr 29. [PubMed:19403853]
  7. Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ: Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology. 2005 Mar;30(3):618-32. [PubMed:15602503]
  8. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 Nov;83(2):339-45. [PubMed:10534607]
  9. Peng X, Knapp BI, Bidlack JM, Neumeyer JL: Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3;50(9):2254-8. Epub 2007 Apr 4. [PubMed:17407276]
Details
2. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Kishioka S, Ko MC, Woods JH: Diltiazem enhances the analgesic but not the respiratory depressant effects of morphine in rhesus monkeys. Eur J Pharmacol. 2000 May 26;397(1):85-92. [PubMed:10844102]
  2. Hoehe M, Duka T: Opiates increase plasma catecholamines in humans. Psychoneuroendocrinology. 1993;18(2):141-8. [PubMed:8388112]
  3. Zernig G, Lewis JW, Woods JH: Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology (Berl). 1997 Feb;129(3):233-42. [PubMed:9084061]
  4. Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17. [PubMed:9399970]
  5. McNicol ED, Boyce D, Schumann R, Carr DB: Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332. doi: 10.1002/14651858.CD006332.pub2. [PubMed:18425947]
  6. Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend. 2006 Sep 15;84(2):175-81. Epub 2006 Mar 6. [PubMed:16517095]
  7. Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN: The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. J Pharmacol Exp Ther. 2009 Aug;330(2):468-75. doi: 10.1124/jpet.108.150011. Epub 2009 Apr 29. [PubMed:19403853]
  8. Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ: Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology. 2005 Mar;30(3):618-32. [PubMed:15602503]
  9. Meerpohl JJ, Timmer A: [News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction]. Z Gastroenterol. 2008 Sep;46(9):917-21. doi: 10.1055/s-2008-1027720. Epub 2008 Sep 22. [PubMed:18810678]
  10. Peng X, Knapp BI, Bidlack JM, Neumeyer JL: Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3;50(9):2254-8. Epub 2007 Apr 4. [PubMed:17407276]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB: The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52(4):389-96. [PubMed:8093631]
  2. De Souza EB, Schmidt WK, Kuhar MJ: Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402. [PubMed:2826773]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18